Orchard Therapeutics' (ORTX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Orchard Therapeutics (NASDAQ:ORTX – Get Rating) in a report released on Monday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Orchard Therapeutics’ FY2023 earnings at ($6.25) EPS. Separately, Oppenheimer increased their price target on Orchard Therapeutics from $5.00 to $37.00 in a research note on Monday, […]

Related Keywords

United States ,America , ,Strategic Wealth Advisors Group ,Blackrock Inc ,Orchard Therapeutics Plc ,Cantor Fitzgerald ,Millennium Management ,Renaissance Technologies ,America Corp ,Orchard Therapeutics ,Get Rating ,Orchard Therapeutic ,Therapeutics Trading Down ,Therapeutics Plc ,Orchard Therapeutics Daily ,Nasdaq Ortx ,Xortx ,Medical ,Reiterated Rating ,